Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMM
Telo Genomics Reports Substantial Progress Toward Clinical Launch of TeloView-SMM
Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to provide an update on the planned launch of the TeloViewSMM (Smoldering Multiple Myeloma) assay in the fourth quarter of this year. The test will be introduced to clinicians as a Research Use Only (RUO) tool via Telo's new physician experience program. The program, designated as SMART (Smoldering Multiple myeloma Assessment of Risk for Transformation), is intended for oncology/hematology physicians and their staff in the U.S. to gain experience ordering and utilizing the TeloView SMM assay.
安大略省多倫多-(Newsfile Corp.-2023年8月29日)-Telo基因公司(多倫多證券交易所股票代碼：TELO)(OTCQB：TDSGF)(以下簡稱“公司”或“Telo”)高興地提供了計劃於今年第四季度推出的TeloViewSMM(陰燃多發性骨髓瘤)檢測的最新情況。這項測試將通過Telo的新醫生體驗計劃作為僅供研究使用(RUO)的工具介紹給臨床醫生。該計劃被指定為聰明(陰燃多發性骨髓瘤轉化風險評估)，旨在為美國的腫瘤/血液內科醫生及其員工提供訂購和使用TeloView SMM測試的經驗。
Telo's CEO Kris Weinberg said, "The planned 2023 launch of SMART along with recent presentations of data at ASCO and EHA are important steps in building Telo's commercial presence in the U.S. Working with a select group of physicians and facilities, the SMART program will gather information and feedback that are critical to the successful launch of TeloView-SMM."
Telo的首席執行官Kris Weinberg說：“計劃於2023年推出的SMART以及最近在ASCO和EHA上展示的數據是建立Telo在美國的商業存在的重要步驟。SMART計劃將與選定的醫生和設施合作，收集對成功推出TeloView-SMM至關重要的資訊和反饋。”
About TeloView-SMM
關於TeloView-SMM
TeloView-SMM has the potential to be an important tool for physicians managing the care of patients diagnosed with Smoldering Multiple Myeloma. The proprietary assay (and associated platform technology) quantifies individual patients' risk of transformation/progression by measuring the 3D structure and spatial organization of telomeres. This molecular signature identifies high-risk SMM patients who are likely to benefit from earlier treatment intervention. The larger subset of low-risk patients may not require immediate treatment and can be regularly monitored using the TeloView-SMM assay along with standard phenotypic measures. Over 200,000 patients in the United States are currently living with smoldering Multiple Myeloma. The TeloView-SMM assay has a potential total addressable market of over 500,000 tests per year.
TeloView-SMM有可能成為醫生管理診斷為陰燃多發性骨髓瘤患者護理的重要工具。這種專有的檢測(以及相關的平臺技術)通過測量端粒的3D結構和空間組織來量化個體患者轉化/進展的風險。這一分子特徵確定了可能從早期治療幹預中受益的高危SMM患者。較大的低風險患者亞群可能不需要立即治療，可以使用TeloView-SMM分析和標準表型測量一起定期監測。美國目前有超過20萬名患者患有陰燃的多發性骨髓瘤。TeloView-SMM測試的潛在總市場每年超過500,000次測試。
About Telo Genomics
關於Telo基因組學
Telo Genomics is a clinical-stage high complexity laboratory pioneering the most comprehensive telomere platform in the industry. The company has developed powerful predictive and prognostic assay tools in oncology and neurological disease. These applications are facilitated on a liquid biopsy platform that performs quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability. The benefits of the TeloView platform have been substantiated in over 160 peer reviewed publications and 30-plus clinical studies involving more than 3,000 patients.
Telo基因組是一家臨床階段的高複雜性實驗室，開創了業內最全面的端粒平臺。該公司在腫瘤學和神經系統疾病方面開發了強大的預測和預後分析工具。這些應用程式是在液體活檢平臺上促進的，該平臺使用分子生物學和人工智慧對3D端粒進行定量分析，以識別與疾病相關的遺傳不穩定性。TeloView平臺的好處已在160多篇同行評議的出版物和30多項涉及3000多名患者的臨床研究中得到證實。
For more information, visit .
有關更多資訊，請訪問。
Kris Weinberg, CEO
678-429-5582
kris.weinberg@telodx.com
MaRS Centre, South Tower,
101 College Street, Suite 200, Toronto,
ON, M5G 1L7
首席執行官克裡斯·溫伯格
678-429-5582
郵箱：kris.weinberg@telodx.com
火星中心，南塔，
學院街101號，多倫多200號套房，
亮起，M5G 1L7
Cautionary Note Regarding Forward-Looking Statements
有關前瞻性陳述的注意事項
Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "intends", "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the clinical efficacy of products, commercial viability of products, use of proceeds, and the ability of the TeloView platform to deliver personalized medicine resulting in better treatments and outcomes are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
根據加拿大證券法，本文中包含的某些資訊可能構成“前瞻性資訊”。一般而言，前瞻性資訊可以通過使用前瞻性術語來識別，例如“打算”、“將”，或這些詞語和短語的變體，或關於某些行動、事件或結果“將”發生的陳述。有關產品的臨床療效、產品的商業可行性、收益的使用以及TeloView平臺提供個性化藥物以獲得更好的治療和結果的能力的前瞻性陳述是基於公司的估計，受已知和未知的風險、不確定因素和其他因素的影響，這些因素可能會導致公司的實際結果、活動水準、業績或成就與此類前瞻性陳述或前瞻性資訊中明示或暗示的內容大不相同，包括資本支出和其他成本。不能保證這些陳述將被證明是準確的，因為實際結果和未來事件可能與這些陳述中預期的大不相同。因此，讀者不應過分依賴前瞻性陳述和前瞻性資訊。除非適用的證券法要求，否則公司不會更新任何通過引用納入本文的前瞻性陳述或前瞻性資訊。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。